Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Offer for Orchid for Sixth Time

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said it has extended its cash tender offer to purchase Orchid Cellmark to 5 p.m. EDT Oct. 7.

The extension is the sixth by LabCorp since it launched its bid for Orchid in April for $2.80 per share, or a total price tag of $85.4 million. The offer had been previously extended to Sept. 9.

LabCorp received a request from the US Federal Trade Commission in May for additional information about the purchase and said today that it continues to cooperate with the agency's request.

The depositary for the tender offer has told LabCorp that as of 5 p.m. EDT Sept. 9, shareholders of Orchid had validly tendered and not withdrawn more than 26 million shares of the company's stock, including 173,688 shares of stock tendered through notices of guaranteed delivery. The shares tendered make up about 87.2 percent of all outstanding shares of Orchid, and about 86.6 percent excluding the shares tendered by notices of guaranteed delivery.

On a fully diluted basis, the tendered shares represent 80 percent of all outstanding shares of Orchid, and 79.4 percent excluding the shares tendered by guaranteed delivery.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.